Missing the Forest for the Trees: Marketing Systems Approach to Pharmaceutical Industry Marketing Practices

被引:2
作者
Jayanti, Rama K. [1 ]
机构
[1] Cleveland State Univ, Mkt, Cleveland, OH 44115 USA
关键词
conflict of interests; marketing for better world; marketing systems; pharmaceutical marketing; physician trust; CONFLICTS-OF-INTEREST; CONTINUING MEDICAL-EDUCATION; PHYSICIANS; PROMOTION; PERSPECTIVE; AUTHORSHIP; DOCUMENTS; ROFECOXIB; CAMPAIGN; SCIENCE;
D O I
10.1177/02761467211037323
中图分类号
F [经济];
学科分类号
02 ;
摘要
The overall aim of this study is to examine firm strategic choices that trigger negative externalities culminating in market failure, system crisis, and public harm. A conceptual framework of marketing system crisis rooted in conflict of interests (COI) theory is used to make the following arguments: (1) marketing strategies emulated by the industry actors at micro level set lock in through path dependencies, (2) such path dependencies may be associated with negative externalities in the form of reduced quality of life of downstream stakeholders in adjacent systems, (3) back lash by system actors precipitates market failure inviting regulatory oversight in the form of fines that tarnish trust and firm reputation, (4) with implications for system crisis and public welfare. A systematic analysis of court documents pertaining to pharmaceutical industry settlements bolstered by sales data from the company reports and Medicaid reimbursement data indicate that, for the case examined, diverse marketing practices are systematically developed with the strategic intent to insert external incentives that influence physician judgment and trigger market failure through negative externalities. Implications for marketing for a better world, systems health, pharmaceutical marketing, and suggestions for incorporating COI principles into theories of marketing for a better world conclude the paper.
引用
收藏
页码:231 / 246
页数:16
相关论文
共 95 条
[1]  
AAMC, 2008, AAMC CALLS STRICT LI
[2]   Industry-sponsored clinical research - A broken system [J].
Angell, Marcia .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (09) :1069-1071
[3]  
[Anonymous], 2017, STATE DRUG UTILIZATI
[4]  
[Anonymous], 1991, Journal of Macromarketing, DOI DOI 10.1177/027614679101100208
[5]  
[Anonymous], 2008, NEW YORK TIMES
[6]  
Arndt Johan., 1986, MARK MANAG, P121
[7]  
Arthur W.Brian., 1988, EC EVOLVING COMPLEX, P9, DOI [10.1201/9780429492846-2, DOI 10.1201/9780429492846-2]
[8]   Scope and impact of financial conflicts of interest in biomedical research - A systematic review [J].
Bekelman, JE ;
Li, Y ;
Gross, CP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (04) :454-465
[9]  
Bhattacharya CB, 2010, J PUBLIC POLICY MARK, V29, P1
[10]   Health industry practices that create conflicts of interest - A policy proposal for academic medical centers [J].
Brennan, TA ;
Rothman, DJ ;
Blank, L ;
Blumenthal, D ;
Chimonas, SC ;
Cohen, JJ ;
Goldman, J ;
Kassirer, JP ;
Kimball, H ;
Naughton, J ;
Smelser, N .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (04) :429-433